Advertisement
- Taiwan
- /
- Medical Equipment
- /
- TWSE:1733
Apex Biotechnology Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Apex Biotechnology (TWSE:1733) Full Year 2024 Results
Key Financial Results
- Revenue: NT$1.85b (up 11% from FY 2023).
- Net income: NT$128.0m (up 11% from FY 2023).
- Profit margin: 6.9% (in line with FY 2023).
- EPS: NT$1.28 (up from NT$1.16 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Apex Biotechnology EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates by 21%.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
We should say that we've discovered 2 warning signs for Apex Biotechnology that you should be aware of before investing here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TWSE:1733
Apex Biotechnology
Researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide.
Flawless balance sheet with proven track record.
Similar Companies
Market Insights
Advertisement
Weekly Picks
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.888.1% undervalued
48 followersusers have followed this narrative
3 commentsusers have commented on this narrative
22 likesusers have liked this narrative
TO
Tokyo on LVMH Moët Hennessy - Louis Vuitton Société Européenne ·
EU#4 - Turning Heritage into the World’s Strongest Luxury Empire
Fair Value:€750.0428.5% undervalued
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
9 likesusers have liked this narrative
WE
WealthAP on Alphabet ·
The "Easy Money" Is Gone: Why Alphabet Is Now a "Show Me" Story
Fair Value:US$386.4316.5% undervalued
65 followersusers have followed this narrative
1 commentusers have commented on this narrative
20 likesusers have liked this narrative
Recently Updated Narratives
AS
asaa on Norwegian Air Shuttle ·
Norwegian Air Shuttle's revenue will grow by 73.56% and profitability will soar
Fair Value:NOK 20091.7% undervalued
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
andre_santos on Alphabet ·
Alphabet - A Fundamental and Historical Valuation
Fair Value:US$274.4317.6% overvalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AL
alex30free on Swedencare ·
The Compound Effect: From Acquisition to Integration
Fair Value:SEK 46.2846.1% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
OO
OOO97 on Neo Performance Materials ·
Undervalued Key Player in Magnets/Rare Earth
Fair Value:CA$25.3322.3% undervalued
75 followersusers have followed this narrative
0 commentsusers have commented on this narrative
19 likesusers have liked this narrative
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.888.1% undervalued
48 followersusers have followed this narrative
3 commentsusers have commented on this narrative
22 likesusers have liked this narrative
WE
WealthAP on PayPal Holdings ·
The "Sleeping Giant" Stumbles, Then Wakes Up
Fair Value:US$8250.7% undervalued
88 followersusers have followed this narrative
6 commentsusers have commented on this narrative
35 likesusers have liked this narrative
Trending Discussion
KA
Kalibrator on Ubisoft Entertainment ·
As a gamer, I would not touch this company now. They are hated by the community and have been releasing major flops on their AAA games during the last 5 years (for good reasons). It is true that the valuation is ridiculously low compared to what the licenses are worth, but if the trend continues the value of those will also decline. Management needs to almost make a 180° turnaround to get things right. I agree that a take-private deal before it is too late might be the best option for an investor entering today. We might also see a split sales of the different studios. It is a very risky play, but potentially with high reward.
1
|0
